首页> Toxins> Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction?

Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction?

导出 OA

翻译打印收藏纠错

第一作者： Lu,Dai

第一单位： Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 141 86 Huddinge, Stockholm, Sweden.

作者： Lu,Dai ^[1] ; Björn K,Meijers ^[2] ; Bert,Bammens ^[2] ; Henriette,de Loor ^[3] ; Leon J,Schurgers ^[4] ; Abdul Rashid,Qureshi ^[1] ; Peter,Stenvinkel ^[1] ; Pieter,Evenepoel ^[2]

作者单位： Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 141 86 Huddinge, Stockholm, Sweden. ^[1] Department of Microbiology Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven-University of Leuven, B-3000 Leuven, Belgium.;Department of Nephrology, University Hospitals Leuven, B-3000 Leuven, Belgium. ^[2] Department of Microbiology Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven-University of Leuven, B-3000 Leuven, Belgium. ^[3] Department of Biochemistry, Cardiovascular Research School Maastricht, Maastricht University, 6200MD Maastricht, The Netherlands. ^[4]

关键词 end-stage kidney disease microbial metabolism sevelamer uremic toxins vitamin K